{"id":"W4389243535","doi":"10.1182/blood-2023-174432","title":"Preliminary Findings of a Phase Ib/II Trial Indicate Manageable Safety and Promising Efficacy for Mosunetuzumab in Combination with Lenalidomide (M+Len) in Previously Untreated (1L) Follicular Lymphoma (FL)","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Lenalidomide; Medicine; Internal medicine; Oncology; Follicular lymphoma; Phases of clinical research; Chemotherapy; Chemotherapy regimen; Lymphoma; Multiple myeloma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002136077,0.0008045611,0.001123033,0.0002193165,0.0003691919,0.0009523278,0.0004991952,0.00107586,0.004055929],"category_scores_gemma":[0.001129263,0.0002423232,0.001037446,0.0002629233,0.0005177741,0.0006109154,0.0002932117,0.00236549,0.0009435073],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008045377,"about_ca_system_score_gemma":0.001081323,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006863968,"about_ca_topic_score_gemma":0.003086383,"domain_scores_codex":[0.9995905,0.0001923977,0.00002610996,0.00005813673,0.00005043166,0.00008255751],"domain_scores_gemma":[0.9991795,0.0002179305,0.0001517349,0.00005442514,0.00006795219,0.0003283981],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.3766844,0.05527927,0.02570174,0.002189782,0.003215543,0.0008842281,0.0005675325,0.00370852,0.1217693,0.0008330442,0.02016036,0.3890063],"study_design_scores_gemma":[0.3502781,0.5566307,0.03844198,0.0002189803,0.002085893,0.001485445,0.0001123548,0.003067643,0.02296089,0.0007426206,0.02391242,0.00006288226],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9722038,0.006272503,0.001919376,0.003076815,0.000176473,0.004281132,0.003904394,0.0002526273,0.007912863],"genre_scores_gemma":[0.9796562,0.00280569,0.004073493,0.002598594,0.0001949369,0.002505373,0.005342877,0.00004744509,0.002775433],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004055929,"threshold_uncertainty_score":0.0135684,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02330380192520908,"score_gpt":0.3039656633172796,"score_spread":0.2806618613920706,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}